SAN DIEGO and SPRINGFIELD, Mass. – March 15, 2017— Human Longevity, Inc. (HLI), the genomics-based, health intelligence company and Massachusetts Mutual Life Insurance Co. (MassMutual), announced today they have signed an innovative multi-year agreement to offer HLI’s whole genome sequencing product, HLIQ Whole Genome, to eligible MassMutual customers, employees and financial professionals at a reduced price. The initiative should help enable HLI’s goal of providing up to 200,000 HLIQ Whole Genome reports.
“MassMutual has long believed that both financial and physical health are important, inextricably linked components of individual well-being,” said Gareth Ross, MassMutual’s Chief Digital and Customer Experience Officer. “Our cutting-edge agreement with HLI – which is unlike anything else in our industry – may better enable our customers, employees and financial professionals to see the benefits of a long and healthy life.”
HLIQ Whole Genome, which is ordered by a client’s physician, includes comprehensive sequencing and analysis of the individual’s whole genome. The report may give insight into health status and risk for disease, details on which pharmaceuticals may work better for individuals, carrier status for family planning decisions, along with ancestry and personal traits. Clients and their doctors will receive an electronic version of the genome report and their entire genome in a printable poster format.
HLI’s data security standards are designed to fully protect client data. MassMutual will not receive from HLI any data, including genomic data, on these policyowners, customers, employees or financial professionals. MassMutual does not pay for or otherwise subsidize the cost of the HLIQ Whole Genome. This voluntary program is available to existing MassMutual customers as of March 14, 2017.
Cynthia Collins, HLI Chief Executive Officer stated, “Current practice of medicine is reactive, focused on management of disease and costly. The HLIQ Whole Genome is one of HLI’s novel solutions to help make healthcare more predictive, proactive, and preventative. We continue to believe that genomics will play an increasingly important role across a variety of business sectors including insurance and look forward to working with MassMutual.”
HLI has developed one of the world’s largest databases, which currently has approximately 40,000 genomes and related phenotype (physical trait) data. This distinct database, combined with HLI’s proprietary tools and machine learning capabilities, may enable HLI to make new discoveries from the genome, which could lead to more novel insights for customers. Clients also have the added benefit of knowing that their genomic data is helping to enhance the overall understanding of health and disease.
The offer is available through March 14, 2018.To learn more about HLIQ Whole Genome, customers should start by visiting MassMutual’s website at www.massmutual.com/hli. More information about HLI and HLIQ Whole Genome can be found at www.humanlongevity.com.